
    
      The study will employ a standard 3+3 dose escalation design to determine maximum tolerated
      dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose
      expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle
      (21 days).
    
  